BRCA-associated protein 1 mutant cholangiocarcinoma: an aggressive disease subtype

Journal of Gastrointestinal Oncology

Claudius Conrad²  Jean-Nicolas Vauthey²  Deepa Anand¹  Rachna T. Shroff¹  Humaid O. Al-Shamsi¹  Milind M. Javle¹  Mingxin Zuo¹  Apurva Jain¹ 

[1] Department of Gastrointestinal Medical Oncology,The University of Texas MD Anderson Cancer Center, Houston, Texas, USADepartment of Gastrointestinal Medical Oncology,The University of Texas MD Anderson Cancer Center, Houston, Texas, USADepartment of Gastrointestinal Medical Oncology,The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USADepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USADepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

关键词: BAP1-mutant cholangiocarcinoma;    next-generation sequencing (NGS);    Foundation Medicine;    gemcitabine;    cisplatin;   

DOI  :  10.21037/jgo.2016.03.05

学科分类：肿瘤学

来源: Pioneer Bioscience Publishing Company

【 授权许可】

Unknown